BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32067259)

  • 1. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
    Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
    Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
    Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
    Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
    Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
    J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
    Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
    Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim FDG
    Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
    Kitadate A; Narita K; Fukumoto K; Terao T; Tsushima T; Kobayashi H; Abe Y; Miura D; Takeuchi M; Machida Y; Matsue K
    Cancer Med; 2020 Aug; 9(15):5509-5518. PubMed ID: 32558387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
    Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
    Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
    Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
    J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
    Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
    Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients.
    Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A
    Clin Cancer Res; 2020 Jan; 26(2):373-383. PubMed ID: 31645353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim PET in Diffuse Large B-Cell Lymphoma.
    Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
    J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
    Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
    Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
    Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Extensive Analysis of
    Louarn N; Galicier L; Bertinchamp R; Lussato D; Montravers F; Oksenhendler É; Merlet P; Gérard L; Vercellino L
    J Clin Oncol; 2022 Apr; 40(12):1346-1355. PubMed ID: 35073166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.